ViroGates announces that the development and regulatory approval of the suPARnostic® TurbiLatex product for Roche Diagnostics cobas c500 and c700 series has been completed.

The suPARnostic® TurbiLatex product is a latex particle-enhanced turbidimetric immunoassay.

The Roche cobas c500 and c700 series are the market leading instruments for performing immunochemical analysis in the hospitals across Europe. According to Roche Diagnostics, more than 20,000 cobas instruments are installed worldwide, each with a throughput volume of up to 1,000 tests per hour.

suPARnostic® Turbilatex enables automatic handling of blood samples at clinical chemistry laboratories, and now all commercially relevant instruments within the Roche Diagnostic cobas series will be able to run suPARnostic® TurbiLatex tests.

Validation on other turbidimetric platforms will follow.